Conjunctival melanoma is a rare ocular cancer, and despite recent advances in the early detection of metastasis and the availability of new drugs such as immune checkpoint inhibitors and Braf-directed targeted therapy that have demonstrated efficacy for the treatment of metastatic conjunctival melanoma,1 it remains a significant cause of morbidity and mortality worldwide. Jain et al report on 29 patients with metastatic conjunctival melanoma.2 These 29 patients represent about 10% of the 288 patients with conjunctival melanoma included in this retrospective review based on data pooled from 10 international centres from a wide geographic area of the world. ‘Metastasis’ is defined as ‘M1’ per the American Joint Commission on Cancer (AJCC) definition and as such only addresses distant (hematogenous) metastasis. In other words, the stated primary objective of the report is to focus on patients who developed hematogenous distant metastasis although the authors provide some information regarding nodal metastasis in the same group of patients. Among the 29 patients with systemic metastasis, five (17%) were found at the time of the initial presentation, while 24 (83%) were …

中文翻译：

---

转移性结膜黑色素瘤患者的预后


结膜黑色素瘤是一种罕见的眼癌，尽管最近在转移的早期检测方面取得了进展，并且免疫检查点抑制剂和 Braf 定向靶向治疗等新药已证明对治疗转移性结膜黑色素瘤有效，1 但它仍然是全球发病率和死亡率的重要原因。Jain 等人报告了 29 名转移性结膜黑色素瘤患者。这 29 名患者约占本回顾性综述中纳入的 288 名结膜黑色素瘤患者的 10%，该患者基于来自世界广泛地理区域的 10 个国际中心汇集的数据。根据美国癌症联合委员会 （AJCC） 的定义，“转移”被定义为“M1”，因此仅指远处（血行）转移。换句话说，该报告的既定主要目标是关注发生血源性远处转移的患者，尽管作者提供了有关同一组患者淋巴结转移的一些信息。在 29 例全身转移患者中，5 例 （17%） 在初次就诊时被发现，而 24 例 （83%） 在初次就诊时被发现。